<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Protein Cell</journal-id>
<journal-id journal-id-type="iso-abbrev">Protein Cell</journal-id>
<journal-title-group>
<journal-title>Protein &amp; Cell</journal-title>
</journal-title-group>
<issn pub-type="ppub">1674-800X</issn>
<issn pub-type="epub">1674-8018</issn>
<publisher>
<publisher-name>Higher Education Press</publisher-name>
<publisher-loc>Beijing</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28434148</article-id>
<article-id pub-id-type="pmc">5563282</article-id>
<article-id pub-id-type="publisher-id">410</article-id>
<article-id pub-id-type="doi">10.1007/s13238-017-0410-x</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ren</surname>
<given-names>Jiangtao</given-names>
</name>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3041-2535</contrib-id>
<name>
<surname>Zhao</surname>
<given-names>Yangbing</given-names>
</name>
<address>
<email>Yangbing@upenn.edu</email>
</address>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 8972</institution-id><institution-id institution-id-type="GRID">grid.25879.31</institution-id><institution>Center for Cellular Immunotherapies, Perelman School of Medicine, </institution><institution>University of Pennsylvania, </institution></institution-wrap>Philadelphia, PA 19104-5156 USA </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>22</day>
<month>4</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>22</day>
<month>4</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<month>9</month>
<year>2017</year>
</pub-date>
<volume>8</volume>
<issue>9</issue>
<fpage>634</fpage>
<lpage>643</lpage>
<history>
<date date-type="received">
<day>7</day>
<month>2</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>30</day>
<month>3</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2017</copyright-statement>
<license license-type="OpenAccess">
<license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<p id="Par1">The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 (CRISPR/Cas9) system, an RNA-guided DNA targeting technology, is triggering a revolution in the field of biology. CRISPR/Cas9 has demonstrated great potential for genetic manipulation. In this review, we discuss the current development of CRISPR/Cas9 technologies for therapeutic applications, especially chimeric antigen receptor (CAR) T cell-based adoptive immunotherapy. Different methods used to facilitate efficient CRISPR delivery and gene editing in T cells are compared. The potential of genetic manipulation using CRISPR/Cas9 system to generate universal CAR T cells and potent T cells that are resistant to exhaustion and inhibition is explored. We also address the safety concerns associated with the use of CRISPR/Cas9 gene editing and provide potential solutions and future directions of CRISPR application in the field of CAR T cell immunotherapy. As an integration-free gene insertion method, CRISPR/Cas9 holds great promise as an efficient gene knock-in platform. Given the tremendous progress that has been made in the past few years, we believe that the CRISPR/Cas9 technology holds immense promise for advancing immunotherapy.</p>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>CRISPR/Cas9</kwd>
<kwd>chimeric antigen receptor</kwd>
<kwd>T lymphocytes</kwd>
<kwd>adoptive immunotherapy</kwd>
<kwd>gene therapy</kwd>
</kwd-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© HEP and Springer-Verlag GmbH Germany 2017</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1" sec-type="introduction">
<title>
<bold>INTRODUCTION</bold>
</title>
<p id="Par2">The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 (Cas9) system, a versatile RNA-guided DNA targeting technology, is triggering a revolution in the field of biology. CRISPR/Cas9 has demonstrated great potential for genetic manipulation, even in previously difficult contexts. Here, we review the current development of CRISPR/Cas9 technologies for therapeutic applications, especially chimeric antigen receptor (CAR) T cell-based adoptive immunotherapy. We compare the different methods used to facilitate efficient CRISPR delivery and gene editing in T cells. We explore the potential for genetic manipulation using the CRISPR/Cas9 system to generate universal CAR T cells and potent T cells resistant to exhaustion and inhibition. We discuss safety concerns regarding the specificity and future directions of CRISPR in the field of CAR T cell immunotherapy.</p>
</sec>
<sec id="Sec2">
<title>
<bold>THE CRISPR/CAS9 SYSTEM</bold>
</title>
<p id="Par3">The field of genome editing is evolving rapidly. Until a decade ago, zinc-finger nucleases (ZFNs) were the only practical option available for targeted genome editing (Bibikova et al., <xref ref-type="bibr" rid="CR3">2002</xref>, <xref ref-type="bibr" rid="CR4">2003</xref>; Porteus and Baltimore, <xref ref-type="bibr" rid="CR68">2003</xref>; Urnov et al., <xref ref-type="bibr" rid="CR91">2005</xref>; Morton et al., <xref ref-type="bibr" rid="CR60">2006</xref>; Doyon et al., <xref ref-type="bibr" rid="CR19">2008</xref>; Kim et al., <xref ref-type="bibr" rid="CR43">2009</xref>; Townsend et al., <xref ref-type="bibr" rid="CR89">2009</xref>). Zinc finger proteins recognize target DNA in a modular fashion: each protein consists of at least three zinc finger domains, and a single zinc finger domain interacts with a 3-bp sequence, making them ideal programmable sequence-specific DNA-binding proteins (Pavletich and Pabo, <xref ref-type="bibr" rid="CR64">1991</xref>). In 2011, transcription activator-like effector nucleases (TALENs) emerged as a competitive alternative to ZFNs (Boch et al., <xref ref-type="bibr" rid="CR5">2009</xref>; Moscou and Bogdanove, <xref ref-type="bibr" rid="CR61">2009</xref>; Cermak et al., <xref ref-type="bibr" rid="CR9">2011</xref>; Miller et al., <xref ref-type="bibr" rid="CR59">2011</xref>; Briggs et al., <xref ref-type="bibr" rid="CR7">2012</xref>). Unlike zinc fingers, each repeat domain in TALE proteins recognizes a single base. Four different repeat domains can be mixed and matched to create new DNA-binding proteins, which can be linked to the FokI domain to create a new class of programmable target DNA nucleases (Miller et al., <xref ref-type="bibr" rid="CR59">2011</xref>). These molecules enable precise targeting and cutting at a specific genomic locus to generate double-strand breaks (DSBs) followed by nonhomologous end joining (NHEJ) or homology-directed repair (HDR)-mediated repair, thereby enabling precise genome editing. Studies using these two classes of nucleases have led to important scientific discoveries and therapeutic development. In fact, a ZFN-based treatment of HIV that disables the HIV co-receptor C-C chemokine receptor type 5 (CCR5) in human primary T cells is currently in clinical trials and has shown great promise (Perez et al., <xref ref-type="bibr" rid="CR65">2008</xref>; Tebas et al., <xref ref-type="bibr" rid="CR87">2014</xref>). However, the recognition of the target DNA sequence by these protein-based genome engineering systems is determined by protein sequences. Tedious and complex protein engineering and optimization are therefore required for each specific target DNA sequence, and delivering many of these proteins into cells for simultaneous multiplexed genetic manipulation is challenging. Given these difficulties, their use for large-scale genomic manipulation or genetic screens has been limited.</p>
<p id="Par4">The CRISPR/Cas9 technology originates from type II CRISPR/Cas9 systems, which provide bacteria with adaptive immunity to viruses, plasmids, and other foreign nucleic acids (Barrangou et al., <xref ref-type="bibr" rid="CR2">2007</xref>; Horvath and Barrangou, <xref ref-type="bibr" rid="CR34">2010</xref>; Wiedenheft et al., <xref ref-type="bibr" rid="CR94">2012</xref>). Type II CRISPR systems incorporate sequences from invading DNA between CRISPR repeat sequences that are encoded as arrays within the bacterial host genome. Transcripts from the CRISPR repeat arrays are processed into CRISPR RNAs (crRNAs) (Deltcheva et al., <xref ref-type="bibr" rid="CR17">2011</xref>), each containing a variable sequence transcribed from the invading DNA, which is known as the “protospacer” sequence, and part of the CRISPR repeat. Each crRNA hybridizes with a second RNA, which is known as the transactivating CRISPR RNA (tracrRNA) (Deltcheva et al., <xref ref-type="bibr" rid="CR17">2011</xref>), and these two RNAs form a complex with the Cas9 DNA endonuclease (Jinek et al., <xref ref-type="bibr" rid="CR40">2012</xref>). The protospacer-encoded portion of the crRNA guides Cas9 to complementary target DNA sequences and cleaves the DNA if they are adjacent to short sequences known as protospacer adjacent motifs (PAMs). The type II CRISPR system from Streptococcus pyogenes has been adapted for inducing sequence-specific DSBs and targeted genome editing. In 2012, Jinek et al. first demonstrated that the Cas9 protein from Streptococcus pyogenes (SpCas9) can bind with a tracrRNA-crRNA RNA complex to induce DSBs <italic>in vitro</italic> at a target DNA sequence by Watson-Crick base pairing of crRNA and target DNA (Jinek et al., <xref ref-type="bibr" rid="CR40">2012</xref>). This study also showed that directing Cas9 to bind and cleave a specific DNA sequence did not require an RNA complex. The process can be simply achieved by using a designed, chimeric single guide RNA (sgRNA). In 2013, two groups from MIT and Harvard demonstrated the feasibility of genome editing of human cells using the CRISPR/Cas9 system (Cong et al., <xref ref-type="bibr" rid="CR14">2013</xref>; Mali et al., <xref ref-type="bibr" rid="CR56">2013b</xref>). These discoveries paved the way and opened the era for the use of CRISPR/Cas9 in genome engineering, including gene editing and gene expression regulation, epigenetic modification, and genome imaging (Cheng et al., <xref ref-type="bibr" rid="CR11">2013</xref>; DiCarlo et al., <xref ref-type="bibr" rid="CR18">2013</xref>; Gilbert et al., <xref ref-type="bibr" rid="CR26">2013</xref>; Hwang et al., <xref ref-type="bibr" rid="CR38">2013</xref>; Li et al., <xref ref-type="bibr" rid="CR47">2013</xref>; Maeder et al., <xref ref-type="bibr" rid="CR52">2013</xref>; Nekrasov et al., <xref ref-type="bibr" rid="CR63">2013</xref>; Perez-Pinera et al., <xref ref-type="bibr" rid="CR66">2013</xref>; Qi et al., <xref ref-type="bibr" rid="CR70">2013</xref>; Shen et al., <xref ref-type="bibr" rid="CR81">2013</xref>; Wang et al., <xref ref-type="bibr" rid="CR92">2013</xref>; Tanenbaum et al., <xref ref-type="bibr" rid="CR86">2014</xref>; Chavez et al., <xref ref-type="bibr" rid="CR10">2015</xref>; Hilton et al., <xref ref-type="bibr" rid="CR32">2015</xref>; Kearns et al., <xref ref-type="bibr" rid="CR42">2015</xref>; Konermann et al., <xref ref-type="bibr" rid="CR46">2015</xref>).</p>
</sec>
<sec id="Sec3">
<title>
<bold>GENE EDITING AND THERAPEUTIC APPLICATION OF CRISPR/CAS9 IN HUMAN T CELLS</bold>
</title>
<p id="Par5">In addition to generating powerful research tools, genome editing with CRISPR/Cas9 technology holds great promise as a means to produce therapeutic agents or as a therapeutic itself. Although we focus on SpCas9, particularly its use in therapeutic applications and the development of next-generation transformational drugs in T cells, the general outline described here applies to the larger ensemble of CRISPR/Cas9 tools.</p>
<p id="Par6">The therapeutic potential of CRISPR/Cas9 has already been demonstrated in many aspects. CRISPR/Cas9 has been applied as an antimicrobial agent and has been developed to specifically target antibiotic resistance in highly virulent strains of bacteria (Makarova et al., <xref ref-type="bibr" rid="CR54">2006</xref>). Gene therapy applications have also been tested for monogenic diseases. A CFTR gene defect was repaired in cells from human patients with cystic fibrosis <italic>in vitro</italic> in cultured intestinal stem cell organoids using CRISPR-Cas (Schwank et al., <xref ref-type="bibr" rid="CR79">2013</xref>). Correction of the defective gene causing hereditary tyrosinaemia was performed in mice after the hydrodynamic injection of CRISPR components. This application led to an expansion of mutation-corrected hepatocytes <italic>in vivo</italic> and resulted in a rescued phenotype in adult mice (Yin et al., <xref ref-type="bibr" rid="CR98">2014</xref>). Advancing from the described therapeutic treatment to preventative techniques, muscular dystrophy was prevented via germ line gene editing (Long et al., <xref ref-type="bibr" rid="CR51">2014</xref>). The use of CRISPR/Cas9 to treat viral infections, such as HIV and hepatitis B, has also been demonstrated (Zhen et al., <xref ref-type="bibr" rid="CR99">2015</xref>). IPSC resistant to HIV-1 was also generated through genome editing (Hu et al., <xref ref-type="bibr" rid="CR37">2014</xref>; Ye et al., <xref ref-type="bibr" rid="CR97">2014</xref>).</p>
<p id="Par7">The application of genome editing for therapeutic purpose has begun to overlap with the rapidly evolving field of cancer immunotherapy, particularly for the production of next-generation chimeric antigen receptor (CAR) T cells. These modified T cells armed with tumour-targeting receptors have demonstrated great promise in clinical trials treating various leukaemias and lymphomas and may eventually be used to treat solid cancers (Maus et al., <xref ref-type="bibr" rid="CR58">2014</xref>). CARs comprise an extracellular single-chain variable fragment (ScFv) specific to an antigen on tumour cells and an intracellular chimeric signalling domain that drives T cell activation and the killing of tumour cells (Gross et al., <xref ref-type="bibr" rid="CR28">1989</xref>; Irving and Weiss, <xref ref-type="bibr" rid="CR39">1991</xref>; Maher et al., <xref ref-type="bibr" rid="CR53">2002</xref>; Brentjens et al., <xref ref-type="bibr" rid="CR6">2003</xref>; Carpenito et al., <xref ref-type="bibr" rid="CR8">2009</xref>). To date, the best CAR T cell therapy involves targeting CD19, an antigen expressed by B cells and B cell malignancies. Several other CAR T therapies targeting solid tumours antigens, such as Her2/neu, Mesothelin cMet, GD2, interleukin-13 receptor alpha 2 (IL13Rα2), CEA, and EGFR, are currently under evaluation in different phases of clinical trials.</p>
<p id="Par8">Currently, most CAR T clinical trials utilize autologous T cells and might therefore be hampered by the poor quality and quantity of T cells and by the time and expense of manufacturing autologous T cell products. CAR T cell therapy could substantially benefit from allogeneic universal donor T cells, as “off-the-shelf” cells could greatly increase the number of patients who could be treated by a single CAR T cell product. However, endogenous TCR on allogeneic T cells may recognize the alloantigens of the recipient, leading to graft-versus-host disease (GVHD); furthermore, the expression of HLA on the surface of allogeneic T cells causes rapid rejection by the host immune system. In this context, ZFNs and TALENs have been used to knock out endogenous T cell receptor genes in T cells, which could prevent unwanted graft-versus-host reactivity (Provasi et al., <xref ref-type="bibr" rid="CR69">2012</xref>; Torikai et al., <xref ref-type="bibr" rid="CR88">2012</xref>; Poirot et al., <xref ref-type="bibr" rid="CR67">2015</xref>). Genome-editing strategies could also be used to prevent or delay the rejection of CAR T cells by the recipient’s immune system by eliminating or decreasing the expression of histocompatibility antigens on the donor T cells. Future CAR T cell therapies could benefit from combined modification of endogenous TCR genes, histocompatibility genes, and components of signalling pathways. In a previous study, we reported the use of the CRISPR/Cas9 system to simultaneously disrupt multiple genomic loci. CAR T cells deficient in the expression of endogenous T cell receptor (TCR) and HLA class I (HLA-I) were generated that can be used as universal CAR T cells (Ren et al., <xref ref-type="bibr" rid="CR73">2016</xref>).</p>
<p id="Par9">In addition to enabling the generation of universal CAR T cells, genome editing could be used to enhance CAR T cell function by ablating the genes encoding T cell inhibitory receptors or signalling molecules, such as programmed cell death protein 1 (PD1) or cytotoxic T lymphocyte-associated protein 4 (CTLA4) (Lloyd et al., <xref ref-type="bibr" rid="CR50">2013</xref>; Hoos, <xref ref-type="bibr" rid="CR33">2016</xref>; Su et al., <xref ref-type="bibr" rid="CR83">2016</xref>). Indeed, a clinical trial has recently been approved by the US National Institutes of Health (NIH) Recombinant DNA Advisory Committee (RAC) that will be conducted at the University of Pennsylvania. In this clinical trial, PD1 and the endogenous TCR will be knocked out by CRISPR/Cas9 in NY-ESO-1 TCR transduced T cells. The first clinical trial of CRISPR/Cas9 has been initiated. The trial uses CRISPR/Cas9 to knock out PD1 in T cells of patients with lung cancer; however, CAR or TCR will not be introduced into T cells in this trial (Cyranoski, <xref ref-type="bibr" rid="CR16">2016</xref>). Similar trials with PD1-knockout autologous T cells for prostate (NCT02867345), bladder cancer (NCT02863913), and renal cell carcinoma (NCT02867332) are also being initiated. Scientists are seeking to introduce CAR via HDR to eliminate the need to randomly integrate viral delivery systems and control where CAR integrates (Sadelain et al., <xref ref-type="bibr" rid="CR75">2011</xref>; Kalos and June, <xref ref-type="bibr" rid="CR41">2013</xref>). Notably, simply ablating inhibitory molecules can be a double-edged sword. It is important to investigate whether the removal of some inhibitory signals from the T cells leads to the uncontrolled proliferation of cells or to severe autoimmunity.</p>
</sec>
<sec id="Sec4">
<title>
<bold>DELIVERY OF CRISPR/CAS9 IN T CELLS</bold>
</title>
<p id="Par10">The CRISPR/Cas9 system can be directly applied to human cells by transfection with a plasmid that encodes Cas9 and sgRNA (Cong et al., <xref ref-type="bibr" rid="CR14">2013</xref>). The viral delivery of CRISPR components has been extensively demonstrated using lentivirus and retrovirus (Shalem et al., <xref ref-type="bibr" rid="CR80">2014</xref>; Williams et al., <xref ref-type="bibr" rid="CR95">2016</xref>). Gene editing with CRISPR encoded by non-integrating virus, such as adenovirus and adenovirus-associated virus (AAV), has also been reported (Ran et al., <xref ref-type="bibr" rid="CR72">2015</xref>; Swiech et al., <xref ref-type="bibr" rid="CR85">2015</xref>). Recent discoveries of smaller Cas proteins have enabled and enhanced the combination of this technology with vectors that have gained increasing success for their safety profile and efficiency, such as AAV vectors. Due to their relatively low immunogenicity, AAVs are commonly chosen for <italic>in vivo</italic> gene delivery in somatic gene therapy (Friedland et al., <xref ref-type="bibr" rid="CR21">2015</xref>; Ran et al., <xref ref-type="bibr" rid="CR72">2015</xref>). CRISPR delivery via Cas9 ribonucleoproteins (RNP) also exhibited efficient gene editing in human cells (Kim et al., <xref ref-type="bibr" rid="CR44">2014</xref>).</p>
<p id="Par11">Gene disruption in T cells had been achieved by lentiviral and adenoviral delivery of CRISPR components into primary T cells. However, these methods cannot site-specifically insert and occasionally disrupt essential genetic elements, and the gene disruption efficiency was not very high (Wang et al., <xref ref-type="bibr" rid="CR93">2014</xref>; Li et al., <xref ref-type="bibr" rid="CR48">2015</xref>). Recently, a Jurkat T cell-based lentiviral CRISPR toolbox was developed to facilitate the research on T cell function. Given the flexible and easy-to-handle features of Jurkat T cells, and programmability with different Cas9 variants, the toolbox might serve as a useful platform for the study of T cell signal transductions (Chi et al., <xref ref-type="bibr" rid="CR12">2016</xref>). Although gene ablation in T cells with DNA nucleofection of CRISPR reagents was also achieved, DNA nucleofection is associated with high toxicity to T cells, which represents a major difficulty for its application (Mandal et al., <xref ref-type="bibr" rid="CR57">2014</xref>; Su et al., <xref ref-type="bibr" rid="CR83">2016</xref>). Schumann et al. reported the site-specific genome editing of primary human T cells using Cas9 RNPs (Schumann et al., <xref ref-type="bibr" rid="CR78">2015</xref>). Cas9 RNPs are recombinant Cas9 proteins complexed with <italic>in vitro</italic>-transcribed sgRNAs. Cas9 RNPs delivered via electroporation efficiently ablate CXCR4 and PD-1 expression in CD4 T cells by introducing insertions or deletions (indels) in the targeted region. Furthermore, the inclusion of a HDR template successfully introduced exogenous DNA into the genome at the Cas9 cleavage site. Deep sequencing results indicated that up to 55% of the treated cells contained indels in the targeted region, with 20% of the cells incorporating the exogenous DNA sequence introduced through the HDR template.</p>
<p id="Par12">The work by Schumann et al. is joined by other recent reports focused on primary human T cell gene editing using CRISPR/Cas9. Hendel et al. reported the disruption of CCR5 locus in T cells by co-delivering Cas9 mRNA or protein with chemically modified sgRNAs via electroporation, achieving up to 49% target mutagenesis in activated primary human T cells calculated by tracking of indels by decomposition (TIDE) analysis (Hendel et al., <xref ref-type="bibr" rid="CR31">2015</xref>).</p>
<p id="Par13">A major challenge in primary T-cell engineering lies in the limited time frame in which genetic manipulation can be accomplished with high efficiency. Unstimulated primary or naïve T cells are significantly less receptive to exogenous nucleic acid or protein uptake compared with stimulated T cells (Hendel et al., <xref ref-type="bibr" rid="CR31">2015</xref>). By contrast, repeated stimulation will lead to T-cell exhaustion and decrease its anti-tumour efficacy. Therefore, protocol optimization will be required to enable the effective application of multiple genetic manipulation techniques on one T-cell product. To this end, we recently reported a method to incorporate disrupting endogenous genes into standard clinical CAR T cell manufacturing processes (Ren et al., <xref ref-type="bibr" rid="CR73">2016</xref>). Freshly isolated human T cells were stimulated via anti- CD3/CD28 beads and lentivirally transduced at 1 day post-stimulation to stably express a CAR transgene, and T cells were electroporated at days 3 and 4 with RNA-encoding Cas9 and sgRNA to disrupt TCR, HLA-I, and PD1 simultaneously. The editing efficiency using this combined protocol was donor dependent, with the results indicating &gt;70% CAR transduction efficiency and &gt;60% double-knockout efficiency in most production runs. This manufacturing procedure yielded CAR T cells that were specific to CD19 targets, resistant to host rejection, and incapable of triggering GVHD, thus highlighting the ability to generate multi-functional universal CAR T cells with CRISPR/Cas9 techniques. Similar results were also reported using another approach of CRISPR/Cas9 RNPs targeting the same 3 genes: TCR, B2m, and PD1 (Liu et al., <xref ref-type="bibr" rid="CR49">2017</xref>). Compared to multiple deliveries of sgRNAs, multiplex genome editing with Cas9 RNP in T cells reduced the toxicity associated with RNA electroporations at the cost of decreased gene targeting efficiency. The authors used multiple sgRNAs targeting the same gene to improve gene disruption efficiency, which may potentially increase the off-target effects. To further improve the application of multiplex genome editing and to reduce the toxicity associated with multiple electroporation, we developed a One-shot CRISPR system, by incorporation of multiple gRNAs in a CAR lentiviral vector. Efficient multiple gene modification can be achieved by a single electroporation of various Cas9 mRNAs (Ren et al., <xref ref-type="bibr" rid="CR74">2017</xref>). A brief summary of various delivery methods of CRISPR/Cas9 components into T cells is schematically presented in Fig. <xref ref-type="fig" rid="Fig1">1</xref>. A comparison between different methods for CRISPR gene editing in T cell is presented in Table <xref ref-type="table" rid="Tab1">1</xref>.<fig id="Fig1"><label>Figure 1</label><caption><p>
<bold>A brief summary of various delivery methods of CRISPR/Cas9 components into T cells</bold>
</p></caption><graphic id="MO1" xlink:href="13238_2017_410_Fig1_HTML"></graphic></fig>
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Comparison of various delivery methods of CRISPR/Cas for T cell gene editing</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3"></th><th align="left" colspan="4">Viral-delivery</th><th align="left" colspan="4">Non-viral-delivery</th></tr><tr><th align="left" colspan="2">Integrating virus</th><th align="left" colspan="2">Integrating-free virus</th><th align="left" colspan="2">Single electroporation</th><th align="left" colspan="2">Double electroporation</th></tr><tr><th align="left">Lentivirus</th><th align="left">Retrovirus</th><th align="left">Adenovirus</th><th align="left">AAV</th><th align="left">Plasmid</th><th align="left">RNP</th><th align="left">Chem-RNA</th><th align="left">RNA</th></tr></thead><tbody><tr><td align="left">Integration</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">No</td><td align="left">No</td><td align="left">Rear</td><td align="left">No</td><td align="left">No</td><td align="left">No</td></tr><tr><td align="left">Efficiency</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Medium</td><td align="left">Medium</td><td align="left">High</td></tr><tr><td align="left">Electroporation</td><td align="left">No</td><td align="left">No</td><td align="left">No</td><td align="left">No</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Yes</td></tr><tr><td align="left">Toxicity</td><td align="left">Medium</td><td align="left">Medium</td><td align="left">Low</td><td align="left">Low</td><td align="left">High</td><td align="left">Low</td><td align="left">Low</td><td align="left">Medium</td></tr><tr><td align="left">Off-target effects</td><td align="left">Medium</td><td align="left">Medium</td><td align="left">Low</td><td align="left">Low</td><td align="left">Medium</td><td align="left">Rear</td><td align="left">Low</td><td align="left">Rear</td></tr></tbody></table><table-wrap-foot><p>RNP: Cas9 protein-sgRNA complex; Chem-RNA: Cas9 protein or mRNA complexed with chemically modified sgRNA; RNA: Cas9 mRNA and sgRNA</p></table-wrap-foot></table-wrap>
</p>
<p id="Par14">These Cas9-based gene-editing techniques will enable the disruption of a wide variety of target genes, including endogenous TCR, the checkpoint receptors PD1 or CTLA-4 in tumour-targeting T cells or the virally targeted chemokine receptors CCR5 and CXCR4 in T cells of HIV patients. The insertion of exogenous DNA sequences using HDR templates demonstrated by Schumann et al. further opens the possibility of precisely integrating transgenic elements, thereby reducing the risk of gene integration in oncogenic sites caused by viruses. However, the current efficiency of site-specific gene knock-in by nuclease-mediated homologous recombination is not comparable to that of standard viral transduction. Thus, the next step for gene editing in T cells will be to develop protocols that enable the combinatorial application of various gene-editing techniques in primary T cells.</p>
</sec>
<sec id="Sec5">
<title>
<bold>SAFETY ISSUES AND CONCERNS</bold>
</title>
<p id="Par15">The off-target activities of Cas9 can be measured by directly assessing the potential off-target genomic DNA sites defined by the sequences that have 1–6 nucleotide (nt) differences to the intended target sequence. A given 20-nt target sequence might have hundreds of such potential off-targets within the human genome. The T7 Endonuclease I (T7E1) mutation mismatch assay is commonly used to detect high indel frequencies (&gt;2%–5%). As a result, more sensitive deep sequencing assays are needed to identify lower frequency off-target mutations (Cho et al., <xref ref-type="bibr" rid="CR13">2014</xref>; Fu et al., <xref ref-type="bibr" rid="CR24">2014</xref>). Exome sequencing was also used for off-target analysis, but the high false negative result rate associated with exome sequencing analysis limits its interpretation of the results. However, accurately predicting the off-target cleavage sites remains a challenge because it is typically biased, given the inability of most available algorithms for off-target prediction to cover all potential off-target sites. The genome-wide detection of DSBs provides a non-biased method to assess the specificity of Cas9-mediated DNA cleavage, and several methods have been developed to meet this purpose. In one method called genome-wide unbiased identification of DSBs enabled by sequencing (GUIDE-Seq), the Cas9-sgRNA induced DSBs are tagged in the genomes of living cells by introducing a blunt, double-stranded oligodeoxynucleotide during the end-joining process following a DSB. The double-stranded oligodeoxynucleotide integration sites are then amplified and deep sequenced (Tsai et al., <xref ref-type="bibr" rid="CR90">2015</xref>). A modified high-throughput, genome-wide translocation sequencing (HTGTS) was developed based on linear-amplification-mediated PCR (LAM-PCR HTGTS). LAM-PCR HTGTS enables the detection of DSBs based on translocation to other endogenous or ectopic DSBs using the target DSB as “bait” to capture the “prey” sequences translocated to the target DSB (Frock et al., <xref ref-type="bibr" rid="CR22">2015</xref>). A third method, called <italic>in situ</italic> breaks labelling, enrichments on streptavidin, and next generation sequencing (BLESS), captures biotinylated oligonucleotides labelled DSBs in fixed cells using streptavidin. Enriched DSB-containing DNA fragments are PCR amplified and analysed by deep sequencing (Crosetto et al., <xref ref-type="bibr" rid="CR15">2013</xref>; Ran et al., <xref ref-type="bibr" rid="CR72">2015</xref>). A fourth method called digested genome sequencing (Digenome-Seq) uses isolated genomic DNA for <italic>in vitro</italic> Cas9-mediated digestion followed by whole-genome sequencing to evaluate genome-wide Cas9 off-target effects (Kim et al., <xref ref-type="bibr" rid="CR45">2015</xref>).</p>
<p id="Par16">CRISPR/Cas9 generally disrupts their intended target sites reliably; however, an important question to consider is to what extent these nucleases induce off-target cleavage events, especially in therapeutic application. CRISPR/Cas9 gene editing generates off-target mutations depending upon the experimental setting and cell type (Cho et al., <xref ref-type="bibr" rid="CR13">2014</xref>). Pankaj et al. reported an extremely low incidence of off-target mutagenesis of CRISPR in hematopoietic stem cells (Mandal et al., <xref ref-type="bibr" rid="CR57">2014</xref>). Recent studies also demonstrated a low incidence of off-target mutagenesis in T cells using lentivirus and adenovirus-delivered CRISPR/Cas9 to knockout CCR5 (Wang et al., <xref ref-type="bibr" rid="CR93">2014</xref>; Li et al., <xref ref-type="bibr" rid="CR48">2015</xref>). Another report showed no detectable off-target mutations in the CXCR4-knockout CD4 T cells (Hou et al., <xref ref-type="bibr" rid="CR35">2015</xref>). We reported rare off-target mutagenesis targeting TRAC or TRBC with Cas9 (Ren et al., <xref ref-type="bibr" rid="CR73">2016</xref>). Although these studies all suggest that T cells might be minimally tolerable to CRISPR/Cas9-induced off-target mutagenesis, non-biased strategies combined with deep sequencing for off-target detections should be applied to the selected target gRNA used in the clinical trials.</p>
</sec>
<sec id="Sec6">
<title>
<bold>FUTURE DIRECTIONS</bold>
</title>
<p id="Par17">Reducing the off-target effects for safe therapeutic application of CRISPR/Cas9 in immunotherapy remains unresolved. Various approaches have been explored to improve the specificity of CRISPR/Cas9. The choice of proper target sequence is the first and most effective option to improve the specificity. All published studies have suggested that the CRISPR/Cas9 mediated off-target mutagenesis could vary depending on the sgRNA design and target sequence. Predictive algorithms have been developed to facilitate this process by computationally searching target sequences that bear the least similarities to other sequences to reduce the off-target effects.</p>
<p id="Par18">Precisely tuning the amount of Cas9 and sgRNA in cells is also used to improve the specificity; some studies have demonstrated that a decrease in the amount of CRISPR reagents in cells could reduce off-target effects (Fu et al., <xref ref-type="bibr" rid="CR23">2013</xref>; Hsu et al., <xref ref-type="bibr" rid="CR36">2013</xref>). Timely controlled Cas9 expression is also demonstrated through a tet-on system (Gonzalez et al., <xref ref-type="bibr" rid="CR27">2014</xref>). Furthermore, gene editing with the Cas9 mRNA and protein causes fewer off-target effects compared to plasmids and viruses, likely because the mRNA or RNPs were rapidly degraded after immediate on-target cleavage (Kim et al., <xref ref-type="bibr" rid="CR44">2014</xref>). Modifying the sgRNA sequence also improved the specificity. For example, sgRNA with a truncated base-pairing sequence (17 nt instead of 20 nt) enhanced the targeting specificity because truncated sgRNAs have reduced binding affinity with the target DNA and thus are more sensitive to mismatches (Fu et al., <xref ref-type="bibr" rid="CR24">2014</xref>).</p>
<p id="Par19">An alternative approach is to take advantage of the Cas9 nickase that contains mutations in one of the two nuclease domains, HNH or RuvC, which cleave the DNA strand complementary and noncomplementary (respectively) to the sgRNA (Gasiunas et al., <xref ref-type="bibr" rid="CR25">2012</xref>; Jinek et al., <xref ref-type="bibr" rid="CR40">2012</xref>). A pair of Cas9 nickases could generate two single-strand breaks adjacent to each other on opposite DNA strands when guided by two properly designed sgRNAs (Mali et al., <xref ref-type="bibr" rid="CR55">2013a</xref>; Ran et al., <xref ref-type="bibr" rid="CR71">2013</xref>; Cho et al., <xref ref-type="bibr" rid="CR13">2014</xref>). The paired nickases exhibit higher specificity in editing because the generation of DSBs requires two independent binding events, whereas the nuclease Cas9 requires only one binding event. A similar strategy is to fuse DNA-endonuclease-dead Cas9 (dCas9) to the dimerizing FokI nuclease. The dCas9-FokI fusion is an RNA-guided nuclease that cleaves DNA only when a pair of FokI domains is sufficiently close to form a dimer. Efficient cleavage occurs when two target sites are spaced approximately 13–25 bp apart (Guilinger et al., <xref ref-type="bibr" rid="CR29">2014</xref>; Wyvekens et al., <xref ref-type="bibr" rid="CR96">2015</xref>). Moreover, because the FokI nuclease activity relies on dimerization, this strategy also reduced unwanted mutagenesis compared to the Cas9 nickase (Guilinger et al., <xref ref-type="bibr" rid="CR29">2014</xref>; Wyvekens et al., <xref ref-type="bibr" rid="CR96">2015</xref>). However, these approaches improve CRISPR specificity at the cost of reduced efficiency.</p>
<p id="Par20">Facilitated by the crystal structure of SpCas9, two recent studies have reported more precise genomic edits with rationally engineered CRISPR/Cas9 systems. Slaymaker et al. created systematic single or multiple mutations in the positively charged residues that are predicted to be involved in the interaction with the non-target strand of the target DNA and identified Cas9 mutants that decrease off-target effects without impairing on-target activity (Slaymaker et al., <xref ref-type="bibr" rid="CR82">2016</xref>). Using a similar approach, Kleinstiver et al. made a quadruple amino acid substituted SpCas9 that retains high on-target activity with minimal off-target activity. Application and further exploration of high-fidelity Cas9 variants will increase the reliability of CRISPR/Cas9 as both a research tool and a therapeutic approach.</p>
<p id="Par21">As an integration-free gene insertion method, CRISPR/Cas9 holds great promise as an efficient gene knock-in platform. Conventional CAR expression in T cells requires randomly integrating viral delivery vectors, including lentivirus and retrovirus. However, uncontrolled virus integration in host cell genomes has the potential risk of causing insertional mutagenesis. CRISPR/Cas9 mediates efficient gene knock-in in human cells, embryos, and plants. Schumann et al. reported successful introduction of exogenous DNA into T cells genome at the Cas9 cleavage site. Although the knock-in of large fragments, such as a CAR in T cells, remains challenging, doing so is desirable for therapeutic application and needs further exploration. Sather et al. reported the feasibility of knock-in of a CAR transgene in T cells with MegaTal and an AAV HDR template (Sather et al., <xref ref-type="bibr" rid="CR77">2015</xref>). A more recent study showed that targeting a CAR to the TRAC locus greatly enhanced the antitumor activity by reducing tonic activation (Eyquem et al., <xref ref-type="bibr" rid="CR20">2017</xref>). Microhomology Mediated End Joining (MMEJ) has been used for gene knock-in in human cells and animals wherein large homology arm is not required, thus facilitating gene delivery with small inserts (Nakade et al., <xref ref-type="bibr" rid="CR62">2014</xref>; Sakuma et al., <xref ref-type="bibr" rid="CR76">2015</xref>). Previously, some studies have highlighted the possibility of knock-in of large gene cassettes using homology-independent targeted integration strategy, which enables robust DNA knock-in in both dividing and non-dividing cells <italic>in vitro</italic> and, more importantly, <italic>in vivo</italic> (Auer et al., <xref ref-type="bibr" rid="CR1">2014</xref>; He et al., <xref ref-type="bibr" rid="CR30">2016</xref>; Suzuki et al., <xref ref-type="bibr" rid="CR84">2016</xref>).</p>
<p id="Par22">Given the tremendous progress that has been made in the past several years, we believe that the CRISPR/Cas9 technology holds immense promise for advancing immunotherapy.</p>
</sec>
</body>
<back>
<ack>
<title>
<bold>ACKNOWLEDGMENTS</bold>
</title>
<p>This work was supported by a US National Institutes of Health (NIH) Grants YZ (2R01CA120409).</p>
<sec id="FPar1">
<title>
<bold>ABBREVIATIONS</bold>
</title>
<p id="Par23">AAV, adenovirus-associated virus; CAR, chimeric antigen receptor; CRISPR, clustered regularly interspaced short palindromic repeats; Cas9, CRISPR-associated 9; CTLA4, cytotoxic T lymphocyte-associated protein 4; DSBs, double-strand breaks; GVHD, graft-versus-host disease; HDR, homology-directed repair; HTGTS, high-throughput, genome-wide translocation sequencing; IL13Rα2, interleukin-13 receptor alpha 2; NHEJ, nonhomologous end joining; nt, nucleotide; PAMs, protospacer adjacent motifs; PD1, programmed cell death protein 1; RNP, ribonucleoproteins; ScFv, single-chain variable fragment; sgRNA, single guide RNA; TALENs, transcription activator-like effector nucleases; ZFNs, zinc-finger nucleases</p>
</sec>
<sec id="d29e907">
<title>COMPLIANCE WITH ETHICS GUIDELINES</title>
<p>Yangbing Zhao has financial interests due to intellectual property and patents in the field of cell and gene therapy. Conflicts of interest are managed in accordance with University of Pennsylvania policy and oversight. Jiangtao Ren declares that he has no conflicts of interest.</p>
<p>This article does not contain any studies with human or animal subjects performed by the any of the authors.</p>
</sec>
</ack>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Auer</surname>
<given-names>TO</given-names>
</name>
<name>
<surname>Duroure</surname>
<given-names>K</given-names>
</name>
<name>
<surname>De Cian</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Concordet</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Del Bene</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Highly efficient CRISPR/Cas9-mediated knock-in in zebrafish by homology-independent DNA repair</article-title>
<source/>Genome Res
          <year>2014</year>
<volume>24</volume>
<fpage>142</fpage>
<lpage>153</lpage>
<pub-id pub-id-type="doi">10.1101/gr.161638.113</pub-id>
<pub-id pub-id-type="pmid">24179142</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barrangou</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Fremaux</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Deveau</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Richards</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Boyaval</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Moineau</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Romero</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Horvath</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>CRISPR provides acquired resistance against viruses in prokaryotes</article-title>
<source/>Science
          <year>2007</year>
<volume>315</volume>
<fpage>1709</fpage>
<lpage>1712</lpage>
<pub-id pub-id-type="doi">10.1126/science.1138140</pub-id>
<pub-id pub-id-type="pmid">17379808</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bibikova</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Golic</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Golic</surname>
<given-names>KG</given-names>
</name>
<name>
<surname>Carroll</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Targeted chromosomal cleavage and mutagenesis in <italic>Drosophila</italic> using zinc-finger nucleases</article-title>
<source/>Genetics
          <year>2002</year>
<volume>161</volume>
<fpage>1169</fpage>
<lpage>1175</lpage>
<pub-id pub-id-type="pmid">12136019</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bibikova</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Beumer</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Trautman</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Carroll</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Enhancing gene targeting with designed zinc finger nucleases</article-title>
<source/>Science
          <year>2003</year>
<volume>300</volume>
<fpage>764</fpage>
<pub-id pub-id-type="doi">10.1126/science.1079512</pub-id>
<pub-id pub-id-type="pmid">12730594</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boch</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Scholze</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Schornack</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Landgraf</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hahn</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kay</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lahaye</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nickstadt</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bonas</surname>
<given-names>U</given-names>
</name>
</person-group>
<article-title>Breaking the code of DNA binding specificity of TAL-type III effectors</article-title>
<source/>Science
          <year>2009</year>
<volume>326</volume>
<fpage>1509</fpage>
<lpage>1512</lpage>
<pub-id pub-id-type="doi">10.1126/science.1178811</pub-id>
<pub-id pub-id-type="pmid">19933107</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brentjens</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Latouche</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Santos</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Marti</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Gong</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Lyddane</surname>
<given-names>C</given-names>
</name>
<name>
<surname>King</surname>
<given-names>PD</given-names>
</name>
<name>
<surname>Larson</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Weiss</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Riviere</surname>
<given-names>I</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15</article-title>
<source/>Nat Med
          <year>2003</year>
<volume>9</volume>
<fpage>279</fpage>
<lpage>286</lpage>
<pub-id pub-id-type="doi">10.1038/nm827</pub-id>
<pub-id pub-id-type="pmid">12579196</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Briggs</surname>
<given-names>AW</given-names>
</name>
<name>
<surname>Rios</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Chari</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Mali</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Church</surname>
<given-names>GM</given-names>
</name>
</person-group>
<article-title>Iterative capped assembly: rapid and scalable synthesis of repeat-module DNA such as TAL effectors from individual monomers</article-title>
<source/>Nucleic Acids Res
          <year>2012</year>
<volume>40</volume>
<fpage>e117</fpage>
<pub-id pub-id-type="doi">10.1093/nar/gks624</pub-id>
<pub-id pub-id-type="pmid">22740649</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carpenito</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Milone</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Hassan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Simonet</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Lakhal</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Suhoski</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Varela-Rohena</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Haines</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Heitjan</surname>
<given-names>DF</given-names>
</name>
<name>
<surname>Albelda</surname>
<given-names>SM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains</article-title>
<source/>Proc Natl Acad Sci USA
          <year>2009</year>
<volume>106</volume>
<fpage>3360</fpage>
<lpage>3365</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0813101106</pub-id>
<pub-id pub-id-type="pmid">19211796</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cermak</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Doyle</surname>
<given-names>EL</given-names>
</name>
<name>
<surname>Christian</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Baller</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Somia</surname>
<given-names>NV</given-names>
</name>
<name>
<surname>Bogdanove</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Voytas</surname>
<given-names>DF</given-names>
</name>
</person-group>
<article-title>Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting</article-title>
<source/>Nucleic Acids Res
          <year>2011</year>
<volume>39</volume>
<fpage>e82</fpage>
<pub-id pub-id-type="doi">10.1093/nar/gkr218</pub-id>
<pub-id pub-id-type="pmid">21493687</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chavez</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Scheiman</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Vora</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Pruitt</surname>
<given-names>BW</given-names>
</name>
<name>
<surname>Tuttle</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Iyer</surname>
<given-names>PRE</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kiani</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Guzman</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Wiegand</surname>
<given-names>DJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Highly efficient Cas9-mediated transcriptional programming</article-title>
<source/>Nat Methods
          <year>2015</year>
<volume>12</volume>
<fpage>326</fpage>
<lpage>328</lpage>
<pub-id pub-id-type="doi">10.1038/nmeth.3312</pub-id>
<pub-id pub-id-type="pmid">25730490</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheng</surname>
<given-names>AW</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Katz</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Theunissen</surname>
<given-names>TW</given-names>
</name>
<name>
<surname>Rangarajan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Shivalila</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Dadon</surname>
<given-names>DB</given-names>
</name>
<name>
<surname>Jaenisch</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system</article-title>
<source/>Cell Res
          <year>2013</year>
<volume>23</volume>
<fpage>1163</fpage>
<lpage>1171</lpage>
<pub-id pub-id-type="doi">10.1038/cr.2013.122</pub-id>
<pub-id pub-id-type="pmid">23979020</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Weiss</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>A CRISPR-based toolbox for studying T cell signal transduction</article-title>
<source/>Biomed Res Int
          <year>2016</year>
<volume>2016</volume>
<fpage>5052369</fpage>
<pub-id pub-id-type="pmid">27057542</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cho</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kweon</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Bae</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>JS</given-names>
</name>
</person-group>
<article-title>Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases</article-title>
<source/>Genome Res
          <year>2014</year>
<volume>24</volume>
<fpage>132</fpage>
<lpage>141</lpage>
<pub-id pub-id-type="doi">10.1101/gr.162339.113</pub-id>
<pub-id pub-id-type="pmid">24253446</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cong</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ran</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Cox</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Barretto</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Habib</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Hsu</surname>
<given-names>PD</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Marraffini</surname>
<given-names>LA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Multiplex genome engineering using CRISPR/Cas systems</article-title>
<source/>Science
          <year>2013</year>
<volume>339</volume>
<fpage>819</fpage>
<lpage>823</lpage>
<pub-id pub-id-type="doi">10.1126/science.1231143</pub-id>
<pub-id pub-id-type="pmid">23287718</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crosetto</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Mitra</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Bienko</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dojer</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Karaca</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Chiarle</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Skrzypczak</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ginalski</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Nucleotide-resolution DNA double-strand break mapping by next-generation sequencing</article-title>
<source/>Nat Methods
          <year>2013</year>
<volume>10</volume>
<fpage>361</fpage>
<lpage>365</lpage>
<pub-id pub-id-type="doi">10.1038/nmeth.2408</pub-id>
<pub-id pub-id-type="pmid">23503052</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cyranoski</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>CRISPR gene-editing tested in a person for the first time</article-title>
<source/>Nature
          <year>2016</year>
<volume>539</volume>
<fpage>479</fpage>
<pub-id pub-id-type="doi">10.1038/nature.2016.20988</pub-id>
<pub-id pub-id-type="pmid">27882996</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deltcheva</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Chylinski</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Gonzales</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Chao</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Pirzada</surname>
<given-names>ZA</given-names>
</name>
<name>
<surname>Eckert</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Vogel</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Charpentier</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>CRISPR RNA maturation by <italic>trans</italic>-encoded small RNA and host factor RNase III</article-title>
<source/>Nature
          <year>2011</year>
<volume>471</volume>
<fpage>602</fpage>
<lpage>607</lpage>
<pub-id pub-id-type="doi">10.1038/nature09886</pub-id>
<pub-id pub-id-type="pmid">21455174</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>DiCarlo</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Norville</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Mali</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Rios</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Aach</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Church</surname>
<given-names>GM</given-names>
</name>
</person-group>
<article-title>Genome engineering in <italic>Saccharomyces cerevisiae</italic> using CRISPR-Cas systems</article-title>
<source/>Nucleic Acids Res
          <year>2013</year>
<volume>41</volume>
<fpage>4336</fpage>
<lpage>4343</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gkt135</pub-id>
<pub-id pub-id-type="pmid">23460208</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Doyon</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>McCammon</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Faraji</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Ngo</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Katibah</surname>
<given-names>GE</given-names>
</name>
<name>
<surname>Amora</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hocking</surname>
<given-names>TD</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Rebar</surname>
<given-names>EJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Heritable targeted gene disruption in zebrafish using designed zinc-finger nucleases</article-title>
<source/>Nat Biotechnol
          <year>2008</year>
<volume>26</volume>
<fpage>702</fpage>
<lpage>708</lpage>
<pub-id pub-id-type="doi">10.1038/nbt1409</pub-id>
<pub-id pub-id-type="pmid">18500334</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eyquem</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mansilla-Soto</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Giavridis</surname>
<given-names>T</given-names>
</name>
<name>
<surname>van der Stegen</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Hamieh</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cunanan</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Odak</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gonen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sadelain</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection</article-title>
<source/>Nature
          <year>2017</year>
<volume>543</volume>
<fpage>113</fpage>
<lpage>117</lpage>
<pub-id pub-id-type="doi">10.1038/nature21405</pub-id>
<pub-id pub-id-type="pmid">28225754</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Friedland</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Baral</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Singhal</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Loveluck</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sanchez</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Marco</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Gotta</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Maeder</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Kennedy</surname>
<given-names>EM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Characterization of <italic>Staphylococcus aureus</italic> Cas9: a smaller Cas9 for all-in-one adeno-associated virus delivery and paired nickase applications</article-title>
<source/>Genome Biol
          <year>2015</year>
<volume>16</volume>
<fpage>257</fpage>
<pub-id pub-id-type="doi">10.1186/s13059-015-0817-8</pub-id>
<pub-id pub-id-type="pmid">26596280</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frock</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Meyers</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>YJ</given-names>
</name>
<name>
<surname>Kii</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Alt</surname>
<given-names>FW</given-names>
</name>
</person-group>
<article-title>Genome-wide detection of DNA double-stranded breaks induced by engineered nucleases</article-title>
<source/>Nat Biotechnol
          <year>2015</year>
<volume>33</volume>
<fpage>179</fpage>
<lpage>186</lpage>
<pub-id pub-id-type="doi">10.1038/nbt.3101</pub-id>
<pub-id pub-id-type="pmid">25503383</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Foden</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Khayter</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Maeder</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Reyon</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Joung</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Sander</surname>
<given-names>JD</given-names>
</name>
</person-group>
<article-title>High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells</article-title>
<source/>Nat Biotechnol
          <year>2013</year>
<volume>31</volume>
<fpage>822</fpage>
<lpage>826</lpage>
<pub-id pub-id-type="doi">10.1038/nbt.2623</pub-id>
<pub-id pub-id-type="pmid">23792628</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Sander</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Reyon</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Cascio</surname>
<given-names>VM</given-names>
</name>
<name>
<surname>Joung</surname>
<given-names>JK</given-names>
</name>
</person-group>
<article-title>Improving CRISPR-Cas nuclease specificity using truncated guide RNAs</article-title>
<source/>Nat Biotechnol
          <year>2014</year>
<volume>32</volume>
<fpage>279</fpage>
<lpage>284</lpage>
<pub-id pub-id-type="doi">10.1038/nbt.2808</pub-id>
<pub-id pub-id-type="pmid">24463574</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gasiunas</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Barrangou</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Horvath</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Siksnys</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria</article-title>
<source/>Proc Natl Acad Sci USA
          <year>2012</year>
<volume>109</volume>
<fpage>E2579</fpage>
<lpage>2586</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1208507109</pub-id>
<pub-id pub-id-type="pmid">22949671</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gilbert</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Larson</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Morsut</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Brar</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Torres</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Stern-Ginossar</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Brandman</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Whitehead</surname>
<given-names>EH</given-names>
</name>
<name>
<surname>Doudna</surname>
<given-names>JA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes</article-title>
<source/>Cell
          <year>2013</year>
<volume>154</volume>
<fpage>442</fpage>
<lpage>451</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2013.06.044</pub-id>
<pub-id pub-id-type="pmid">23849981</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gonzalez</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>ZD</given-names>
</name>
<name>
<surname>Lelli</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Verma</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>QV</given-names>
</name>
<name>
<surname>Huangfu</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>An iCRISPR platform for rapid, multiplexable, and inducible genome editing in human pluripotent stem cells</article-title>
<source/>Cell Stem Cell
          <year>2014</year>
<volume>15</volume>
<fpage>215</fpage>
<lpage>226</lpage>
<pub-id pub-id-type="doi">10.1016/j.stem.2014.05.018</pub-id>
<pub-id pub-id-type="pmid">24931489</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gross</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Waks</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Eshhar</surname>
<given-names>Z</given-names>
</name>
</person-group>
<article-title>Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity</article-title>
<source/>Proc Natl Acad Sci USA
          <year>1989</year>
<volume>86</volume>
<fpage>10024</fpage>
<lpage>10028</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.86.24.10024</pub-id>
<pub-id pub-id-type="pmid">2513569</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guilinger</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>DB</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>DR</given-names>
</name>
</person-group>
<article-title>Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification</article-title>
<source/>Nat Biotechnol
          <year>2014</year>
<volume>32</volume>
<fpage>577</fpage>
<lpage>582</lpage>
<pub-id pub-id-type="doi">10.1038/nbt.2909</pub-id>
<pub-id pub-id-type="pmid">24770324</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>D</given-names>
</name>
<name>
<surname>You</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Knock-in of large reporter genes in human cells via CRISPR/Cas9-induced homology-dependent and independent DNA repair</article-title>
<source/>Nucleic Acids Res
          <year>2016</year>
<volume>44</volume>
<fpage>e85</fpage>
<pub-id pub-id-type="doi">10.1093/nar/gkw064</pub-id>
<pub-id pub-id-type="pmid">26850641</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hendel</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bak</surname>
<given-names>RO</given-names>
</name>
<name>
<surname>Clark</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Kennedy</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Ryan</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Roy</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Steinfeld</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Lunstad</surname>
<given-names>BD</given-names>
</name>
<name>
<surname>Kaiser</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Wilkens</surname>
<given-names>AB</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells</article-title>
<source/>Nat Biotechnol
          <year>2015</year>
<volume>33</volume>
<fpage>985</fpage>
<lpage>989</lpage>
<pub-id pub-id-type="doi">10.1038/nbt.3290</pub-id>
<pub-id pub-id-type="pmid">26121415</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hilton</surname>
<given-names>IB</given-names>
</name>
<name>
<surname>D’Ippolito</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Vockley</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Thakore</surname>
<given-names>PI</given-names>
</name>
<name>
<surname>Crawford</surname>
<given-names>GE</given-names>
</name>
<name>
<surname>Reddy</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Gersbach</surname>
<given-names>CA</given-names>
</name>
</person-group>
<article-title>Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers</article-title>
<source/>Nat Biotechnol
          <year>2015</year>
<volume>33</volume>
<fpage>510</fpage>
<lpage>517</lpage>
<pub-id pub-id-type="doi">10.1038/nbt.3199</pub-id>
<pub-id pub-id-type="pmid">25849900</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoos</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Development of immuno-oncology drugs—from CTLA4 to PD1 to the next generations</article-title>
<source/>Nat Rev Drug Discov
          <year>2016</year>
<volume>15</volume>
<fpage>235</fpage>
<lpage>247</lpage>
<pub-id pub-id-type="doi">10.1038/nrd.2015.35</pub-id>
<pub-id pub-id-type="pmid">26965203</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Horvath</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Barrangou</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>CRISPR/Cas, the immune system of bacteria and archaea</article-title>
<source/>Science
          <year>2010</year>
<volume>327</volume>
<fpage>167</fpage>
<lpage>170</lpage>
<pub-id pub-id-type="doi">10.1126/science.1179555</pub-id>
<pub-id pub-id-type="pmid">20056882</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hou</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zhuang</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genome editing of CXCR4 by CRISPR/cas9 confers cells resistant to HIV-1 infection</article-title>
<source/>Sci Rep
          <year>2015</year>
<volume>5</volume>
<fpage>15577</fpage>
<pub-id pub-id-type="doi">10.1038/srep15577</pub-id>
<pub-id pub-id-type="pmid">26481100</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hsu</surname>
<given-names>PD</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Weinstein</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Ran</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Konermann</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Agarwala</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Fine</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Shalem</surname>
<given-names>O</given-names>
</name>
<etal></etal>
</person-group>
<article-title>DNA targeting specificity of RNA-guided Cas9 nucleases</article-title>
<source/>Nat Biotechnol
          <year>2013</year>
<volume>31</volume>
<fpage>827</fpage>
<lpage>832</lpage>
<pub-id pub-id-type="doi">10.1038/nbt.2647</pub-id>
<pub-id pub-id-type="pmid">23873081</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Kaminski</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Cosentino</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Alvarez-Carbonell</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Garcia-Mesa</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Karn</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection</article-title>
<source/>Proc Natl Acad Sci USA
          <year>2014</year>
<volume>111</volume>
<fpage>11461</fpage>
<lpage>11466</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1405186111</pub-id>
<pub-id pub-id-type="pmid">25049410</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hwang</surname>
<given-names>WY</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Reyon</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Maeder</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>SQ</given-names>
</name>
<name>
<surname>Sander</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Peterson</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>Yeh</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Joung</surname>
<given-names>JK</given-names>
</name>
</person-group>
<article-title>Efficient genome editing in zebrafish using a CRISPR-Cas system</article-title>
<source/>Nat Biotechnol
          <year>2013</year>
<volume>31</volume>
<fpage>227</fpage>
<lpage>229</lpage>
<pub-id pub-id-type="doi">10.1038/nbt.2501</pub-id>
<pub-id pub-id-type="pmid">23360964</pub-id>
</element-citation>
</ref>
<ref id="CR39">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Irving</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Weiss</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways</article-title>
<source/>Cell
          <year>1991</year>
<volume>64</volume>
<fpage>891</fpage>
<lpage>901</lpage>
<pub-id pub-id-type="doi">10.1016/0092-8674(91)90314-O</pub-id>
<pub-id pub-id-type="pmid">1705867</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jinek</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Chylinski</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Fonfara</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Hauer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Doudna</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Charpentier</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity</article-title>
<source/>Science
          <year>2012</year>
<volume>337</volume>
<fpage>816</fpage>
<lpage>821</lpage>
<pub-id pub-id-type="doi">10.1126/science.1225829</pub-id>
<pub-id pub-id-type="pmid">22745249</pub-id>
</element-citation>
</ref>
<ref id="CR41">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kalos</surname>
<given-names>M</given-names>
</name>
<name>
<surname>June</surname>
<given-names>CH</given-names>
</name>
</person-group>
<article-title>Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology</article-title>
<source/>Immunity
          <year>2013</year>
<volume>39</volume>
<fpage>49</fpage>
<lpage>60</lpage>
<pub-id pub-id-type="doi">10.1016/j.immuni.2013.07.002</pub-id>
<pub-id pub-id-type="pmid">23890063</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kearns</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Pham</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Tabak</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Genga</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Silverstein</surname>
<given-names>NJ</given-names>
</name>
<name>
<surname>Garber</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Maehr</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Functional annotation of native enhancers with a Cas9-histone demethylase fusion</article-title>
<source/>Nat Methods
          <year>2015</year>
<volume>12</volume>
<fpage>401</fpage>
<lpage>403</lpage>
<pub-id pub-id-type="doi">10.1038/nmeth.3325</pub-id>
<pub-id pub-id-type="pmid">25775043</pub-id>
</element-citation>
</ref>
<ref id="CR43">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>JS</given-names>
</name>
</person-group>
<article-title>Targeted genome editing in human cells with zinc finger nucleases constructed via modular assembly</article-title>
<source/>Genome Res
          <year>2009</year>
<volume>19</volume>
<fpage>1279</fpage>
<lpage>1288</lpage>
<pub-id pub-id-type="doi">10.1101/gr.089417.108</pub-id>
<pub-id pub-id-type="pmid">19470664</pub-id>
</element-citation>
</ref>
<ref id="CR44">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>JS</given-names>
</name>
</person-group>
<article-title>Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins</article-title>
<source/>Genome Res
          <year>2014</year>
<volume>24</volume>
<fpage>1012</fpage>
<lpage>1019</lpage>
<pub-id pub-id-type="doi">10.1101/gr.171322.113</pub-id>
<pub-id pub-id-type="pmid">24696461</pub-id>
</element-citation>
</ref>
<ref id="CR45">
<mixed-citation publication-type="other">Kim D, Bae S, Park J, Kim E, Kim S, Yu HR, Hwang J, Kim JI, Kim JS (2015). Digenome-seq: genome-wide profiling of CRISPR-Cas9 off-target effects in human cells. Nat Methods 12:237–243, 231 p following 243</mixed-citation>
</ref>
<ref id="CR46">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Konermann</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Brigham</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Trevino</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Joung</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Abudayyeh</surname>
<given-names>OO</given-names>
</name>
<name>
<surname>Barcena</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hsu</surname>
<given-names>PD</given-names>
</name>
<name>
<surname>Habib</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Gootenberg</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Nishimasu</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex</article-title>
<source/>Nature
          <year>2015</year>
<volume>517</volume>
<fpage>583</fpage>
<lpage>588</lpage>
<pub-id pub-id-type="doi">10.1038/nature14136</pub-id>
<pub-id pub-id-type="pmid">25494202</pub-id>
</element-citation>
</ref>
<ref id="CR47">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Norville</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Aach</surname>
<given-names>J</given-names>
</name>
<name>
<surname>McCormack</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bush</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Church</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Sheen</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Multiplex and homologous recombination-mediated genome editing in <italic>Arabidopsis</italic> and <italic>Nicotiana benthamiana</italic> using guide RNA and Cas9</article-title>
<source/>Nat Biotechnol
          <year>2013</year>
<volume>31</volume>
<fpage>688</fpage>
<lpage>691</lpage>
<pub-id pub-id-type="doi">10.1038/nbt.2654</pub-id>
<pub-id pub-id-type="pmid">23929339</pub-id>
</element-citation>
</ref>
<ref id="CR48">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Guan</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Griffin</surname>
<given-names>GE</given-names>
</name>
<name>
<surname>Shattock</surname>
<given-names>RJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Inhibition of HIV-1 infection of primary CD4<sup>+</sup> T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR/Cas9</article-title>
<source/>J Gen Virol
          <year>2015</year>
<volume>96</volume>
<fpage>2381</fpage>
<lpage>2393</lpage>
<pub-id pub-id-type="doi">10.1099/vir.0.000139</pub-id>
<pub-id pub-id-type="pmid">25854553</pub-id>
</element-citation>
</ref>
<ref id="CR49">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>AW</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells</article-title>
<source/>Cell Res
          <year>2017</year>
<volume>27</volume>
<fpage>154</fpage>
<lpage>157</lpage>
<pub-id pub-id-type="doi">10.1038/cr.2016.142</pub-id>
<pub-id pub-id-type="pmid">27910851</pub-id>
</element-citation>
</ref>
<ref id="CR50">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lloyd</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Vickery</surname>
<given-names>ON</given-names>
</name>
<name>
<surname>Laugel</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Beyond the antigen receptor: editing the genome of T-cells for cancer adoptive cellular therapies</article-title>
<source/>Front Immunol
          <year>2013</year>
<volume>4</volume>
<fpage>221</fpage>
<pub-id pub-id-type="doi">10.3389/fimmu.2013.00221</pub-id>
<pub-id pub-id-type="pmid">23935598</pub-id>
</element-citation>
</ref>
<ref id="CR51">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Long</surname>
<given-names>C</given-names>
</name>
<name>
<surname>McAnally</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Shelton</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Mireault</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Bassel-Duby</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Olson</surname>
<given-names>EN</given-names>
</name>
</person-group>
<article-title>Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA</article-title>
<source/>Science
          <year>2014</year>
<volume>345</volume>
<fpage>1184</fpage>
<lpage>1188</lpage>
<pub-id pub-id-type="doi">10.1126/science.1254445</pub-id>
<pub-id pub-id-type="pmid">25123483</pub-id>
</element-citation>
</ref>
<ref id="CR52">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maeder</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Linder</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Cascio</surname>
<given-names>VM</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>QH</given-names>
</name>
<name>
<surname>Joung</surname>
<given-names>JK</given-names>
</name>
</person-group>
<article-title>CRISPR RNA-guided activation of endogenous human genes</article-title>
<source/>Nat Methods
          <year>2013</year>
<volume>10</volume>
<fpage>977</fpage>
<lpage>979</lpage>
<pub-id pub-id-type="doi">10.1038/nmeth.2598</pub-id>
<pub-id pub-id-type="pmid">23892898</pub-id>
</element-citation>
</ref>
<ref id="CR53">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maher</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Brentjens</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Gunset</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Riviere</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Sadelain</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor</article-title>
<source/>Nat Biotechnol
          <year>2002</year>
<volume>20</volume>
<fpage>70</fpage>
<lpage>75</lpage>
<pub-id pub-id-type="doi">10.1038/nbt0102-70</pub-id>
<pub-id pub-id-type="pmid">11753365</pub-id>
</element-citation>
</ref>
<ref id="CR54">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Makarova</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Grishin</surname>
<given-names>NV</given-names>
</name>
<name>
<surname>Shabalina</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Wolf</surname>
<given-names>YI</given-names>
</name>
<name>
<surname>Koonin</surname>
<given-names>EV</given-names>
</name>
</person-group>
<article-title>A putative RNA-interference-based immune system in prokaryotes: computational analysis of the predicted enzymatic machinery, functional analogies with eukaryotic RNAi, and hypothetical mechanisms of action</article-title>
<source/>Biol Direct
          <year>2006</year>
<volume>1</volume>
<fpage>7</fpage>
<pub-id pub-id-type="doi">10.1186/1745-6150-1-7</pub-id>
<pub-id pub-id-type="pmid">16545108</pub-id>
</element-citation>
</ref>
<ref id="CR55">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mali</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Aach</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Stranges</surname>
<given-names>PB</given-names>
</name>
<name>
<surname>Esvelt</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Moosburner</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kosuri</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Church</surname>
<given-names>GM</given-names>
</name>
</person-group>
<article-title>CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering</article-title>
<source/>Nat Biotechnol
          <year>2013</year>
<volume>31</volume>
<fpage>833</fpage>
<lpage>838</lpage>
<pub-id pub-id-type="doi">10.1038/nbt.2675</pub-id>
<pub-id pub-id-type="pmid">23907171</pub-id>
</element-citation>
</ref>
<ref id="CR56">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mali</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Esvelt</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Aach</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Guell</surname>
<given-names>M</given-names>
</name>
<name>
<surname>DiCarlo</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Norville</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Church</surname>
<given-names>GM</given-names>
</name>
</person-group>
<article-title>RNA-guided human genome engineering via Cas9</article-title>
<source/>Science
          <year>2013</year>
<volume>339</volume>
<fpage>823</fpage>
<lpage>826</lpage>
<pub-id pub-id-type="doi">10.1126/science.1232033</pub-id>
<pub-id pub-id-type="pmid">23287722</pub-id>
</element-citation>
</ref>
<ref id="CR57">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mandal</surname>
<given-names>PK</given-names>
</name>
<name>
<surname>Ferreira</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Collins</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Meissner</surname>
<given-names>TB</given-names>
</name>
<name>
<surname>Boutwell</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Friesen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Vrbanac</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Garrison</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Stortchevoi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bryder</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9</article-title>
<source/>Cell Stem Cell
          <year>2014</year>
<volume>15</volume>
<fpage>643</fpage>
<lpage>652</lpage>
<pub-id pub-id-type="doi">10.1016/j.stem.2014.10.004</pub-id>
<pub-id pub-id-type="pmid">25517468</pub-id>
</element-citation>
</ref>
<ref id="CR58">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maus</surname>
<given-names>MV</given-names>
</name>
<name>
<surname>Grupp</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Porter</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>June</surname>
<given-names>CH</given-names>
</name>
</person-group>
<article-title>Antibody-modified T cells: CARs take the front seat for hematologic malignancies</article-title>
<source/>Blood
          <year>2014</year>
<volume>123</volume>
<fpage>2625</fpage>
<lpage>2635</lpage>
<pub-id pub-id-type="doi">10.1182/blood-2013-11-492231</pub-id>
<pub-id pub-id-type="pmid">24578504</pub-id>
</element-citation>
</ref>
<ref id="CR59">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miller</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Qiao</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Barlow</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>DF</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Paschon</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Leung</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Hinkley</surname>
<given-names>SJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A TALE nuclease architecture for efficient genome editing</article-title>
<source/>Nat Biotechnol
          <year>2011</year>
<volume>29</volume>
<fpage>143</fpage>
<lpage>148</lpage>
<pub-id pub-id-type="doi">10.1038/nbt.1755</pub-id>
<pub-id pub-id-type="pmid">21179091</pub-id>
</element-citation>
</ref>
<ref id="CR60">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morton</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Jorgensen</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Carroll</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Induction and repair of zinc-finger nuclease-targeted double-strand breaks in <italic>Caenorhabditis elegans</italic> somatic cells</article-title>
<source/>Proc Natl Acad Sci USA
          <year>2006</year>
<volume>103</volume>
<fpage>16370</fpage>
<lpage>16375</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0605633103</pub-id>
<pub-id pub-id-type="pmid">17060623</pub-id>
</element-citation>
</ref>
<ref id="CR61">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moscou</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Bogdanove</surname>
<given-names>AJ</given-names>
</name>
</person-group>
<article-title>A simple cipher governs DNA recognition by TAL effectors</article-title>
<source/>Science
          <year>2009</year>
<volume>326</volume>
<fpage>1501</fpage>
<pub-id pub-id-type="doi">10.1126/science.1178817</pub-id>
<pub-id pub-id-type="pmid">19933106</pub-id>
</element-citation>
</ref>
<ref id="CR62">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nakade</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tsubota</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sakane</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kume</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sakamoto</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Obara</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Daimon</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sezutsu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sakuma</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Microhomology-mediated end-joining-dependent integration of donor DNA in cells and animals using TALENs and CRISPR/Cas9</article-title>
<source/>Nat Commun
          <year>2014</year>
<volume>5</volume>
<fpage>5560</fpage>
<pub-id pub-id-type="doi">10.1038/ncomms6560</pub-id>
<pub-id pub-id-type="pmid">25410609</pub-id>
</element-citation>
</ref>
<ref id="CR63">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nekrasov</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Staskawicz</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Weigel</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Kamoun</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Targeted mutagenesis in the model plant <italic>Nicotiana benthamiana</italic> using Cas9 RNA-guided endonuclease</article-title>
<source/>Nat Biotechnol
          <year>2013</year>
<volume>31</volume>
<fpage>691</fpage>
<lpage>693</lpage>
<pub-id pub-id-type="doi">10.1038/nbt.2655</pub-id>
<pub-id pub-id-type="pmid">23929340</pub-id>
</element-citation>
</ref>
<ref id="CR64">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pavletich</surname>
<given-names>NP</given-names>
</name>
<name>
<surname>Pabo</surname>
<given-names>CO</given-names>
</name>
</person-group>
<article-title>Zinc finger-DNA recognition: crystal structure of a Zif268-DNA complex at 2.1 A</article-title>
<source/>Science
          <year>1991</year>
<volume>252</volume>
<fpage>809</fpage>
<lpage>817</lpage>
<pub-id pub-id-type="doi">10.1126/science.2028256</pub-id>
<pub-id pub-id-type="pmid">2028256</pub-id>
</element-citation>
</ref>
<ref id="CR65">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perez</surname>
<given-names>EE</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Jouvenot</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Bartsevich</surname>
<given-names>VV</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>YL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Establishment of HIV-1 resistance in CD4<sup>+</sup> T cells by genome editing using zinc-finger nucleases</article-title>
<source/>Nat Biotechnol
          <year>2008</year>
<volume>26</volume>
<fpage>808</fpage>
<lpage>816</lpage>
<pub-id pub-id-type="doi">10.1038/nbt1410</pub-id>
<pub-id pub-id-type="pmid">18587387</pub-id>
</element-citation>
</ref>
<ref id="CR66">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perez-Pinera</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kocak</surname>
<given-names>DD</given-names>
</name>
<name>
<surname>Vockley</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Adler</surname>
<given-names>AF</given-names>
</name>
<name>
<surname>Kabadi</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Polstein</surname>
<given-names>LR</given-names>
</name>
<name>
<surname>Thakore</surname>
<given-names>PI</given-names>
</name>
<name>
<surname>Glass</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Ousterout</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Leong</surname>
<given-names>KW</given-names>
</name>
<etal></etal>
</person-group>
<article-title>RNA-guided gene activation by CRISPR-Cas9-based transcription factors</article-title>
<source/>Nat Methods
          <year>2013</year>
<volume>10</volume>
<fpage>973</fpage>
<lpage>976</lpage>
<pub-id pub-id-type="doi">10.1038/nmeth.2600</pub-id>
<pub-id pub-id-type="pmid">23892895</pub-id>
</element-citation>
</ref>
<ref id="CR67">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Poirot</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Philip</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Schiffer-Mannioui</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Le Clerre</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Chion-Sotinel</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Derniame</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Potrel</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Bas</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lemaire</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Galetto</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Multiplex genome-edited T-cell manufacturing platform for “Off-the-Shelf” adoptive T-cell immunotherapies</article-title>
<source/>Cancer Res
          <year>2015</year>
<volume>75</volume>
<fpage>3853</fpage>
<lpage>3864</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-14-3321</pub-id>
<pub-id pub-id-type="pmid">26183927</pub-id>
</element-citation>
</ref>
<ref id="CR68">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Porteus</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Baltimore</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Chimeric nucleases stimulate gene targeting in human cells</article-title>
<source/>Science
          <year>2003</year>
<volume>300</volume>
<fpage>763</fpage>
<pub-id pub-id-type="doi">10.1126/science.1078395</pub-id>
<pub-id pub-id-type="pmid">12730593</pub-id>
</element-citation>
</ref>
<ref id="CR69">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Provasi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Genovese</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Lombardo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Magnani</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>PQ</given-names>
</name>
<name>
<surname>Reik</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Paschon</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Kuball</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer</article-title>
<source/>Nat Med
          <year>2012</year>
<volume>18</volume>
<fpage>807</fpage>
<lpage>815</lpage>
<pub-id pub-id-type="doi">10.1038/nm.2700</pub-id>
<pub-id pub-id-type="pmid">22466705</pub-id>
</element-citation>
</ref>
<ref id="CR70">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qi</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Larson</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Gilbert</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Doudna</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Weissman</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Arkin</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>WA</given-names>
</name>
</person-group>
<article-title>Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression</article-title>
<source/>Cell
          <year>2013</year>
<volume>152</volume>
<fpage>1173</fpage>
<lpage>1183</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2013.02.022</pub-id>
<pub-id pub-id-type="pmid">23452860</pub-id>
</element-citation>
</ref>
<ref id="CR71">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ran</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Hsu</surname>
<given-names>PD</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>CY</given-names>
</name>
<name>
<surname>Gootenberg</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Konermann</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Trevino</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Inoue</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Matoba</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity</article-title>
<source/>Cell
          <year>2013</year>
<volume>154</volume>
<fpage>1380</fpage>
<lpage>1389</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2013.08.021</pub-id>
<pub-id pub-id-type="pmid">23992846</pub-id>
</element-citation>
</ref>
<ref id="CR72">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ran</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Cong</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>WX</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Gootenberg</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Kriz</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Zetsche</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Shalem</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Makarova</surname>
<given-names>KS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>In vivo genome editing using <italic>Staphylococcus aureus</italic> Cas9</article-title>
<source/>Nature
          <year>2015</year>
<volume>520</volume>
<fpage>186</fpage>
<lpage>191</lpage>
<pub-id pub-id-type="doi">10.1038/nature14299</pub-id>
<pub-id pub-id-type="pmid">25830891</pub-id>
</element-citation>
</ref>
<ref id="CR73">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ren</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>June</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition</article-title>
<source/>Clin Cancer Res
          <year>2016</year>
<volume>16</volume>
<fpage>1300</fpage>
</element-citation>
</ref>
<ref id="CR74">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ren</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>June</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>A versatile system for rapid multiplex genome-edited CAR T cell generation</article-title>
<source/>Oncotarget
          <year>2017</year>
<volume>8</volume>
<fpage>17002</fpage>
<lpage>17011</lpage>
<pub-id pub-id-type="pmid">28199983</pub-id>
</element-citation>
</ref>
<ref id="CR75">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sadelain</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Papapetrou</surname>
<given-names>EP</given-names>
</name>
<name>
<surname>Bushman</surname>
<given-names>FD</given-names>
</name>
</person-group>
<article-title>Safe harbours for the integration of new DNA in the human genome</article-title>
<source/>Nat Rev Cancer
          <year>2011</year>
<volume>12</volume>
<fpage>51</fpage>
<lpage>58</lpage>
<pub-id pub-id-type="pmid">22129804</pub-id>
</element-citation>
</ref>
<ref id="CR76">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sakuma</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Takenaga</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kawabe</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Nakamura</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kamihira</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Homologous recombination-independent large gene cassette knock-in in CHO cells using TALEN and MMEJ-directed donor plasmids</article-title>
<source/>Int J Mol Sci
          <year>2015</year>
<volume>16</volume>
<fpage>23849</fpage>
<lpage>23866</lpage>
<pub-id pub-id-type="doi">10.3390/ijms161023849</pub-id>
<pub-id pub-id-type="pmid">26473830</pub-id>
</element-citation>
</ref>
<ref id="CR77">
<mixed-citation publication-type="other">Sather BD, Romano Ibarra GS, Sommer K, Curinga G, Hale M, Khan IF, Singh S, Song Y, Gwiazda K, Sahni J et al (2015) Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci Transl Med 7:307ra156</mixed-citation>
</ref>
<ref id="CR78">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schumann</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Boyer</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Simeonov</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Subramaniam</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gate</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Haliburton</surname>
<given-names>GE</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Bluestone</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Doudna</surname>
<given-names>JA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Generation of knock-in primary human T cells using Cas9 ribonucleoproteins</article-title>
<source/>Proc Natl Acad Sci USA
          <year>2015</year>
<volume>112</volume>
<fpage>10437</fpage>
<lpage>10442</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1512503112</pub-id>
<pub-id pub-id-type="pmid">26216948</pub-id>
</element-citation>
</ref>
<ref id="CR79">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schwank</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Koo</surname>
<given-names>BK</given-names>
</name>
<name>
<surname>Sasselli</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Dekkers</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Heo</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Demircan</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sasaki</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Boymans</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cuppen</surname>
<given-names>E</given-names>
</name>
<name>
<surname>van der Ent</surname>
<given-names>CK</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients</article-title>
<source/>Cell Stem Cell
          <year>2013</year>
<volume>13</volume>
<fpage>653</fpage>
<lpage>658</lpage>
<pub-id pub-id-type="doi">10.1016/j.stem.2013.11.002</pub-id>
<pub-id pub-id-type="pmid">24315439</pub-id>
</element-citation>
</ref>
<ref id="CR80">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shalem</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Sanjana</surname>
<given-names>NE</given-names>
</name>
<name>
<surname>Hartenian</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Mikkelsen</surname>
<given-names>TS</given-names>
</name>
<name>
<surname>Heckl</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ebert</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Root</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Doench</surname>
<given-names>JG</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genome-scale CRISPR-Cas9 knockout screening in human cells</article-title>
<source/>Science
          <year>2014</year>
<volume>343</volume>
<fpage>84</fpage>
<lpage>87</lpage>
<pub-id pub-id-type="doi">10.1126/science.1247005</pub-id>
<pub-id pub-id-type="pmid">24336571</pub-id>
</element-citation>
</ref>
<ref id="CR81">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shen</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>X</given-names>
</name>
</person-group>
<article-title>Generation of gene-modified mice via Cas9/RNA-mediated gene targeting</article-title>
<source/>Cell Res
          <year>2013</year>
<volume>23</volume>
<fpage>720</fpage>
<lpage>723</lpage>
<pub-id pub-id-type="doi">10.1038/cr.2013.46</pub-id>
<pub-id pub-id-type="pmid">23545779</pub-id>
</element-citation>
</ref>
<ref id="CR82">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Slaymaker</surname>
<given-names>IM</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zetsche</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>WX</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Rationally engineered Cas9 nucleases with improved specificity</article-title>
<source/>Science
          <year>2016</year>
<volume>351</volume>
<fpage>84</fpage>
<lpage>88</lpage>
<pub-id pub-id-type="doi">10.1126/science.aad5227</pub-id>
<pub-id pub-id-type="pmid">26628643</pub-id>
</element-citation>
</ref>
<ref id="CR83">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Su</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Shao</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>F</given-names>
</name>
<etal></etal>
</person-group>
<article-title>CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients</article-title>
<source/>Sci Rep
          <year>2016</year>
<volume>6</volume>
<fpage>20070</fpage>
<pub-id pub-id-type="doi">10.1038/srep20070</pub-id>
<pub-id pub-id-type="pmid">26818188</pub-id>
</element-citation>
</ref>
<ref id="CR84">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suzuki</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Tsunekawa</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Hernandez-Benitez</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Hatanaka</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Araoka</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z</given-names>
</name>
<etal></etal>
</person-group>
<article-title>In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration</article-title>
<source/>Nature
          <year>2016</year>
<volume>540</volume>
<fpage>144</fpage>
<lpage>149</lpage>
<pub-id pub-id-type="doi">10.1038/nature20565</pub-id>
<pub-id pub-id-type="pmid">27851729</pub-id>
</element-citation>
</ref>
<ref id="CR85">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Swiech</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Heidenreich</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Banerjee</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Habib</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Trombetta</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sur</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9</article-title>
<source/>Nat Biotechnol
          <year>2015</year>
<volume>33</volume>
<fpage>102</fpage>
<lpage>106</lpage>
<pub-id pub-id-type="doi">10.1038/nbt.3055</pub-id>
<pub-id pub-id-type="pmid">25326897</pub-id>
</element-citation>
</ref>
<ref id="CR86">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tanenbaum</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Gilbert</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Qi</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Weissman</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Vale</surname>
<given-names>RD</given-names>
</name>
</person-group>
<article-title>A protein-tagging system for signal amplification in gene expression and fluorescence imaging</article-title>
<source/>Cell
          <year>2014</year>
<volume>159</volume>
<fpage>635</fpage>
<lpage>646</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2014.09.039</pub-id>
<pub-id pub-id-type="pmid">25307933</pub-id>
</element-citation>
</ref>
<ref id="CR87">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tebas</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Stein</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>WW</given-names>
</name>
<name>
<surname>Frank</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>SQ</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Spratt</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Surosky</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>Giedlin</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Nichol</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV</article-title>
<source/>N Engl J Med
          <year>2014</year>
<volume>370</volume>
<fpage>901</fpage>
<lpage>910</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa1300662</pub-id>
<pub-id pub-id-type="pmid">24597865</pub-id>
</element-citation>
</ref>
<ref id="CR88">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Torikai</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Reik</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>PQ</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Maiti</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Huls</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Kebriaei</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Rabinovich</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR</article-title>
<source/>Blood
          <year>2012</year>
<volume>119</volume>
<fpage>5697</fpage>
<lpage>5705</lpage>
<pub-id pub-id-type="doi">10.1182/blood-2012-01-405365</pub-id>
<pub-id pub-id-type="pmid">22535661</pub-id>
</element-citation>
</ref>
<ref id="CR89">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Townsend</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Wright</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Winfrey</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Maeder</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Joung</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Voytas</surname>
<given-names>DF</given-names>
</name>
</person-group>
<article-title>High-frequency modification of plant genes using engineered zinc-finger nucleases</article-title>
<source/>Nature
          <year>2009</year>
<volume>459</volume>
<fpage>442</fpage>
<lpage>445</lpage>
<pub-id pub-id-type="doi">10.1038/nature07845</pub-id>
<pub-id pub-id-type="pmid">19404258</pub-id>
</element-citation>
</ref>
<ref id="CR90">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsai</surname>
<given-names>SQ</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>NT</given-names>
</name>
<name>
<surname>Liebers</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Topkar</surname>
<given-names>VV</given-names>
</name>
<name>
<surname>Thapar</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Wyvekens</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Khayter</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Iafrate</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Le</surname>
<given-names>LP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases</article-title>
<source/>Nat Biotechnol
          <year>2015</year>
<volume>33</volume>
<fpage>187</fpage>
<lpage>197</lpage>
<pub-id pub-id-type="doi">10.1038/nbt.3117</pub-id>
<pub-id pub-id-type="pmid">25513782</pub-id>
</element-citation>
</ref>
<ref id="CR91">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Urnov</surname>
<given-names>FD</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>YL</given-names>
</name>
<name>
<surname>Beausejour</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Rock</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Augustus</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Jamieson</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Porteus</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Gregory</surname>
<given-names>PD</given-names>
</name>
<name>
<surname>Holmes</surname>
<given-names>MC</given-names>
</name>
</person-group>
<article-title>Highly efficient endogenous human gene correction using designed zinc-finger nucleases</article-title>
<source/>Nature
          <year>2005</year>
<volume>435</volume>
<fpage>646</fpage>
<lpage>651</lpage>
<pub-id pub-id-type="doi">10.1038/nature03556</pub-id>
<pub-id pub-id-type="pmid">15806097</pub-id>
</element-citation>
</ref>
<ref id="CR92">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Shivalila</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Dawlaty</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>AW</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Jaenisch</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering</article-title>
<source/>Cell
          <year>2013</year>
<volume>153</volume>
<fpage>910</fpage>
<lpage>918</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2013.04.025</pub-id>
<pub-id pub-id-type="pmid">23643243</pub-id>
</element-citation>
</ref>
<ref id="CR93">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kimata</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>CCR5 gene disruption via lentiviral vectors expressing Cas9 and single guided RNA renders cells resistant to HIV-1 infection</article-title>
<source/>PLoS ONE
          <year>2014</year>
<volume>9</volume>
<fpage>e115987</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0115987</pub-id>
<pub-id pub-id-type="pmid">25541967</pub-id>
</element-citation>
</ref>
<ref id="CR94">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wiedenheft</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Sternberg</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Doudna</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>RNA-guided genetic silencing systems in bacteria and archaea</article-title>
<source/>Nature
          <year>2012</year>
<volume>482</volume>
<fpage>331</fpage>
<lpage>338</lpage>
<pub-id pub-id-type="doi">10.1038/nature10886</pub-id>
<pub-id pub-id-type="pmid">22337052</pub-id>
</element-citation>
</ref>
<ref id="CR95">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Williams</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Fricano-Kugler</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Getz</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Skelton</surname>
<given-names>PD</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rizzuto</surname>
<given-names>CP</given-names>
</name>
<name>
<surname>Geller</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Luikart</surname>
<given-names>BW</given-names>
</name>
</person-group>
<article-title>A retroviral CRISPR-Cas9 system for cellular autism-associated phenotype discovery in developing neurons</article-title>
<source/>Sci Rep
          <year>2016</year>
<volume>6</volume>
<fpage>25611</fpage>
<pub-id pub-id-type="doi">10.1038/srep25611</pub-id>
<pub-id pub-id-type="pmid">27161796</pub-id>
</element-citation>
</ref>
<ref id="CR96">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wyvekens</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Topkar</surname>
<given-names>VV</given-names>
</name>
<name>
<surname>Khayter</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Joung</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>SQ</given-names>
</name>
</person-group>
<article-title>Dimeric CRISPR RNA-guided FokI-dCas9 nucleases directed by truncated gRNAs for highly specific genome editing</article-title>
<source/>Hum Gene Ther
          <year>2015</year>
<volume>26</volume>
<fpage>425</fpage>
<lpage>431</lpage>
<pub-id pub-id-type="doi">10.1089/hum.2015.084</pub-id>
<pub-id pub-id-type="pmid">26068112</pub-id>
</element-citation>
</ref>
<ref id="CR97">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ye</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Beyer</surname>
<given-names>AI</given-names>
</name>
<name>
<surname>Teque</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Cradick</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Qi</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Bao</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Muench</surname>
<given-names>MO</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5Delta32 mutation confers resistance to HIV infection</article-title>
<source/>Proc Natl Acad Sci USA
          <year>2014</year>
<volume>111</volume>
<fpage>9591</fpage>
<lpage>9596</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1407473111</pub-id>
<pub-id pub-id-type="pmid">24927590</pub-id>
</element-citation>
</ref>
<ref id="CR98">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yin</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Xue</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bogorad</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Benedetti</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Grompe</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Koteliansky</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Sharp</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Jacks</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>DG</given-names>
</name>
</person-group>
<article-title>Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype</article-title>
<source/>Nat Biotechnol
          <year>2014</year>
<volume>32</volume>
<fpage>551</fpage>
<lpage>553</lpage>
<pub-id pub-id-type="doi">10.1038/nbt.2884</pub-id>
<pub-id pub-id-type="pmid">24681508</pub-id>
</element-citation>
</ref>
<ref id="CR99">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hua</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>YH</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wan</surname>
<given-names>DY</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>LH</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>HF</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>X</given-names>
</name>
</person-group>
<article-title>Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus</article-title>
<source/>Gene Ther
          <year>2015</year>
<volume>22</volume>
<fpage>404</fpage>
<lpage>412</lpage>
<pub-id pub-id-type="doi">10.1038/gt.2015.2</pub-id>
<pub-id pub-id-type="pmid">25652100</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>